comparemela.com

Latest Breaking News On - Patrick vermersch - Page 7 : comparemela.com

EMD Serono Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Phase II clinical trial data of evobrutinib demonstrated low disease activity and stable EDSS, with NfL levels, a marker of neuronal injury, remaining low in people with RMS after three and a half

Massachusetts
United-states
Germany
Canada
Kostenloser-wertpapierhandel
Patrick-vermersch
Jan-klatt
University-of-lille
Head-of-development-unit-neurology
Research-in-biology
Merck-kga
Serono-inc

Treatments Compared for Pediatric-Onset Multiple Sclerosis

More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon β-1a (IFNβ-1a) treatment, and the annualized relapse rate is lower with DMF.

France
Patrick-vermersch
Centre-hospitalier-universitaire-de-lille
Healthday-news

Treatments Compared for Pediatric-Onset Multiple Sclerosis

THURSDAY, Oct. 6, 2022 (HealthDay News) More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate

France
Patrick-vermersch
Centre-hospitalier-universitaire-de-lille
Healthday-news
Physicians-briefing

New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)

Press release content from Business Wire. The AP news staff was not involved in its creation.

Austria
Vienna
Wien
Bristol-myers-squibbmedia
Jonathan-sadeh
Hans-peter-hartung
Bristol-myers-squibb
Patrick-vermersch
Bruce-cree
John-deluca
Instagram
Linkedin

1st RRMS Patient Dosed in Phase 1/2 Trial of Immunotherapy IMCY-0141

1st RRMS Patient Dosed in Phase 1/2 Trial of Immunotherapy IMCY-0141
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

France
Belgium
Denis-bedoret
Patrick-vermersch
University-of-lille
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.